The inventive step reflects a general patentability requirement in most patent laws, according to which an invention should be sufficiently inventive (not obvious in view of the prior art using the skilled person’s common general knowledge) in order to be patented / the patent to be held valid. In the United States, rather than ‘inventive step’, the expression ‘non-obviousness’ is used: is the invention an adequate distance beyond or above the state of the art? The assessment of the inventive step varies from one country to another. The European Patent Office uses the so-called problem-and-solution approach to assess inventive step, an instrument also used by several national European courts.
On 10 October 2012, the Court of Appeal handed down its judgment in the case of MedImmune v Novartis*. This was the first of what is expected to be a series of decisions from the Court of Appeal over the next few months which will address how the question of obviousness should be tackled by…
In countries where patents and utility models (sometimes called “petty patents”) co-exist, a recurrent question is which is the level of inventiveness required for utility models as opposed to patents. According to article 8 of Spain’s 1986 Patents Act, which mirrors article 56 of the European Patent Convention, an invention protected by a patent is…
Applying a purposive construction of the claims the Court found no infringement similar to the conclusion in prior parallel proceedings between the parties in the Netherlands, Germany and the United Kingdom. The issue of added matter was left to be addressed in a separate judgment. Click here for the full text of this case. A summary…
By ruling of 10 July 2012, the Court of Turin decided in the first instance an infringement action filed by Italian company Novamont against German and French companies Biotec and Biosphère, for the alleged infringement of three Novamont patents concerning starch based plastic materials used in the production of biodegradable shoppers. The Court denied the…
The District Court of Turin rejected Merck’s requests for a preliminary injunction, finding lack of inventive step of the claimed co-formulation of dorzolamid and timolol based on a prima facie assessment following the problem solution approach of the EPO Boards of Appeal. Click here for the full text of this case. A summary of this…
The interesting six-jurisdiction patent case between two of the world’s leading enzyme manufacturers, the Danish companies Danisco A/S (now part of DuPont) and Novozymes A/S has already been subject to earlier blogs both here and several times on EPLAW and PatLit. To recap the story briefly, Novozymes started the proceedings by applying for a preliminary…
The classic English approach for determining whether a claimed invention is obvious is to compare the prior art and the claimed invention, to identify the differences between the two and to ask whether those differences, viewed without knowledge of the claimed invention, were obvious or required any degree of invention*. This is often contrasted with…
One of the points of contention in cases where inventive step is discussed is which expert is better suited to express an opinion on whether or not the invention would have been obvious for the person skilled in the art. English Courts, for example, have a long-standing tradition of carefully scrutinising the experts presented by…
On 20 March 2012, the Tribunal de Grande Instance of Paris rendered its decision in the case relating to raloxifene, a molecule useful for treating or preventing osteoporosis in post-menopausal women, opposing Teva to Eli Lilly. This decision raises many questions, first concerning drug patents in particular (patentability of second medical use, patentability of the resolution of…
The Court of Appeal confirms the revocation by the District Court of a patent relating to a coformulation of timolol and dorzolamide for the treatment of glaucoma , for lack of inventive step. The combination of these two substances was disclosed before the priority date as a concomitant therapy. The skilled person would turn this…
